Open AccessTofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
Author(s) -
Chandrashekar Byalekere Shivanna,
Chaithra Shenoy,
R Arti Priya
Publication year - 2018
Publication title -
international journal of trichology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.494
H-Index - 22
eISSN - 0974-9241
pISSN - 0974-7753
DOI - 10.4103/ijt.ijt_21_18
Subject(s) - tofacitinib , alopecia areata , janus kinase inhibitor , janus kinase , medicine , dermatology , pharmacology , ruxolitinib , myelofibrosis , receptor , rheumatoid arthritis , bone marrow
Alopecia areata (AA) is a chronic autoimmune disorder characterized by patchy loss of hair from scalp, beard, eyebrows, or rarely even body hair. Rarely, the disease can be widespread and severe leading to loss of entire scalp and body hair causing apprehension and psychological stress in patients. Management of such cases is equally difficult with the available options of topical and systemic immunosuppressant. Tofacitinib, JAK3 inhibitor, is emerging as a promising drug for the management of severe and resistant cases of AA/totalis/universalis.